Cochlear Stock

Cochlear EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Cochlear (COH.AX) as of Jun 27, 2026 is 21.57.In the previous year, EV/EBIT (Enterprise Value to EBIT) was 22.13 — a change of -2.54% (lower).

EV/EBIT

21.57

YoY

-2.54%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Cochlear is 2026 21.57 . EV/EBIT (Enterprise Value to EBIT) of Cochlear was 2025 22.13 . It decreases by -2.54% lower compared to the previous year.

The Cochlear EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2006
2,945 base
Jan 1, 2007
2,711 base
Jan 1, 2008
1,874 base
Jan 1, 2009
2,184 base
Jan 1, 2010
2,018 base
Jan 1, 2011
1,431 base
Jan 1, 2012
2,041 base
Jan 1, 2013
1,836 base
Jan 1, 2014
2,875 base
Jan 1, 2015
2,540 base
Jan 1, 2016
2,596 base
Jan 1, 2017
3,036 base
Jan 1, 2018
2,873 base
Jan 1, 2019
3,608 base
Jan 1, 2020
4,677 base
YEARPRICE-TO-EBIT
2026 est 14,22
2025 32,70
2024 37,38
2023 48,44
2022 34,07
2021 39,92
2020 46,77
2019 36,08
2018 28,73
2017 30,36
2016 25,96
2015 25,40
2014 28,75
2013 18,36
2012 20,41
2011 14,31
2010 20,18
2009 21,84
2008 18,74
2007 27,11
2006 29,45
Access this data via the Eulerpool API
Get Free API Key

Cochlear Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Cochlear's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Cochlear's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Cochlear's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Cochlear grows earnings faster than its peers.

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

EV/EBIT (Enterprise Value to EBIT) of Cochlear amounted to 22.13 21.57

Access this data via the Eulerpool API
Get Free API Key

Valuation — Cochlear

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Cochlear